JPMorgan Chase & Co. Lowers GSK (LON:GSK) Price Target to GBX 1,400

Key Points

• JPMorgan Chase & Co. has lowered its price target for GSK from GBX 1,460 to GBX 1,400, maintaining an "underweight" rating on the stock.
• Other analysts have mixed opinions, with Deutsche Bank setting a GBX 1,450 target and Shore Capital a more optimistic GBX 2,000 target for GSK.
• On the trading day, GSK shares opened at GBX 1,390, reflecting a 0.5% decline in value.

GSK (LON:GSK - Get Free Report) had its target price cut by stock analysts at JPMorgan Chase & Co. from GBX 1,460 ($19.39) to GBX 1,400 ($18.59) in a research note issued to investors on Monday, MarketBeat reports. The firm currently has an "underweight" rating on the stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 0.72% from the company's previous close.

Several other research analysts also recently commented on GSK. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 1,450 ($19.25) price target on shares of GSK in a research note on Thursday. Berenberg Bank reissued a "hold" rating and set a GBX 1,600 ($21.25) target price on shares of GSK in a research report on Friday, July 18th. Finally, Shore Capital reissued a "buy" rating and set a GBX 2,000 ($26.56) target price on shares of GSK in a research report on Wednesday, July 30th.

GSK Trading Down 0.5%

Shares of GSK opened at GBX 1,390 ($18.46) on Monday. GSK has a twelve month low of GBX 1,242.50 ($16.50) and a twelve month high of GBX 1,678.68 ($22.29). The company has a market cap of £56.40 billion, a P/E ratio of 22.45, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company's fifty day simple moving average is GBX 1,434.66 and its 200-day simple moving average is GBX 1,426.66.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported GBX 75.30 ($1.00) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts expect that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In related news, insider Emma Walmsley sold 5,473 shares of GSK stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.24), for a total value of £79,303.77 ($105,303.11). Also, insider Jonathan Symonds bought 1,350 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was bought at an average price of GBX 1,435 ($19.05) per share, with a total value of £19,372.50 ($25,723.68). Insiders purchased 1,905 shares of company stock worth $2,732,835 in the last three months. Corporate insiders own 1.61% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.